REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Novartis S.R.O. (Czech Republic)

Main Activities: Pharmaceutical and Medicine Manufacturing | Research and Development in the Physical, Engineering, and Life Sciences
Full name: Novartis S.R.O. Profile Updated: April 13, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2021 Available in: English Download a sample report

Novartis s.r.o., is subsidiary of the global Novartis group. Company’s portfolio focuses on innovative patent-protected medicines, eye care with surgical, ophthalmology and consumer products, high-quality generic medicines and biosimilars, vaccines and diagnostic tools to protect against life-threatening diseases.

Headquarters
Na Pankraci 1724/129
Prague; The City of Prague; Postal Code: 14000

Contact Details: Purchase the Novartis S.R.O. report to view the information.

Website: http://www.novartis.com

Basic Information
Total Employees:
Purchase the Novartis S.R.O. report to view the information.
Outstanding Shares:
Purchase the Novartis S.R.O. report to view the information.
Registered Capital:
Purchase the Novartis S.R.O. report to view the information.
Incorporation Date:
November 22, 1995
Key Executives
Purchase this report to view the information.
Legal Representative
Purchase this report to view the information.
Proxy
Purchase this report to view the information.
Proxy
Purchase this report to view the information.
Proxy
Purchase this report to view the information.
Proxy
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Novartis S.R.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
10.11%▲
Total operating revenue
9.41%▲
Operating profit (EBIT)
1.3%▲
EBITDA
-22.77%▼
Net Profit (Loss) for the Period
-1.12%▼
Total assets
10.65%▲
Total equity
22.43%▲
Operating Profit Margin (ROS)
-0.35%▼
Net Profit Margin
-0.31%▼
Return on Equity (ROE)
-4.37%▼
Quick Ratio
0.3%▲

Similar companies

Zentiva K.S.
 
Teva Czech Industries S.R.O.
Hartmann - Rico A.S.
 
Roche S.R.O.
Teva Pharmaceuticals Cr, S.R.O.
 
Lohmann & Rauscher, S.R.O.
Molnlycke Health Care Procedurepak S.R.O.
 
Glenmark Pharmaceuticals S.R.O.
Pro.Med.Cs Praha A.S.
 
Boehringer Ingelheim Spol. S R.O.

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo